Stay updated with breaking news from Path Melanoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240...
Castle Biosciences, Inc. will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile tests at the 2024 Winter Clinical Dermatology...
Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash,...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Nov 2, 2023--